Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea
· Delayed Price · Currency is KRW 7,020.00
-130.00 (-1.82%)
Mar 19, 2025, 9:00 AM KST
Vivozon Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 87,601 | 71,318 | 51,564 | 57,560 | 43,592 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | - | Upgrade
|
| Revenue | 87,601 | 71,318 | 51,564 | 57,560 | 43,592 | Upgrade
|
| Revenue Growth (YoY) | 22.83% | 38.31% | -10.42% | 32.04% | -3.03% | Upgrade
|
| Cost of Revenue | 42,194 | 39,997 | 30,128 | 37,921 | 36,461 | Upgrade
|
| Gross Profit | 45,407 | 31,321 | 21,437 | 19,639 | 7,130 | Upgrade
|
| Selling, General & Admin | 37,111 | 25,082 | 23,031 | 28,627 | 10,427 | Upgrade
|
| Research & Development | 3,572 | 2,541 | 1,927 | 3,935 | 2,870 | Upgrade
|
| Operating Expenses | 47,208 | 26,611 | 31,243 | 39,253 | 15,169 | Upgrade
|
| Operating Income | -1,800 | 4,709 | -9,806 | -19,615 | -8,039 | Upgrade
|
| Interest Expense | -2,254 | -2,904 | -5,271 | -7,297 | -10,792 | Upgrade
|
| Interest & Investment Income | 170.39 | 345.14 | 840.79 | 909.59 | 1,274 | Upgrade
|
| Earnings From Equity Investments | -1,470 | -2,821 | - | -691.35 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -58.49 | -6.07 | 125.03 | 999.14 | -774.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -4,160 | -43.59 | -940 | -402.96 | 1,782 | Upgrade
|
| EBT Excluding Unusual Items | -9,572 | -720.44 | -15,051 | -26,097 | -16,549 | Upgrade
|
| Gain (Loss) on Sale of Investments | 7.32 | -812.22 | -4,842 | 69.4 | -3,621 | Upgrade
|
| Gain (Loss) on Sale of Assets | 76.21 | -596.57 | -102.92 | -229.9 | 337.98 | Upgrade
|
| Asset Writedown | -1,054 | -29.21 | -5,252 | -49,590 | -23,990 | Upgrade
|
| Other Unusual Items | - | - | -92.74 | - | - | Upgrade
|
| Pretax Income | -10,543 | -2,158 | -25,342 | -75,848 | -43,822 | Upgrade
|
| Income Tax Expense | 123.68 | 55.27 | 1,509 | -4,833 | 263.27 | Upgrade
|
| Earnings From Continuing Operations | -10,666 | -2,214 | -26,851 | -71,015 | -44,085 | Upgrade
|
| Earnings From Discontinued Operations | 684.46 | -1,143 | -13,827 | - | - | Upgrade
|
| Net Income to Company | -9,982 | -3,357 | -40,677 | -71,015 | -44,085 | Upgrade
|
| Minority Interest in Earnings | - | - | 771.55 | 1,558 | 330.6 | Upgrade
|
| Net Income | -9,982 | -3,357 | -39,906 | -69,457 | -43,754 | Upgrade
|
| Net Income to Common | -9,982 | -3,357 | -39,906 | -69,457 | -43,754 | Upgrade
|
| Shares Outstanding (Basic) | 48 | 48 | 44 | 33 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 48 | 48 | 44 | 33 | 26 | Upgrade
|
| Shares Change (YoY) | -0.41% | 10.23% | 33.41% | 24.52% | 24.63% | Upgrade
|
| EPS (Basic) | -209.00 | -70.00 | -917.27 | -2129.90 | -1670.65 | Upgrade
|
| EPS (Diluted) | -209.00 | -70.00 | -917.27 | -2130.00 | -1670.65 | Upgrade
|
| Free Cash Flow | -2,719 | -1,532 | -9,814 | -27,608 | 3,755 | Upgrade
|
| Free Cash Flow Per Share | -56.93 | -31.94 | -225.59 | -846.59 | 143.39 | Upgrade
|
| Gross Margin | 51.83% | 43.92% | 41.57% | 34.12% | 16.36% | Upgrade
|
| Operating Margin | -2.05% | 6.60% | -19.02% | -34.08% | -18.44% | Upgrade
|
| Profit Margin | -11.39% | -4.71% | -77.39% | -120.67% | -100.37% | Upgrade
|
| Free Cash Flow Margin | -3.10% | -2.15% | -19.03% | -47.96% | 8.62% | Upgrade
|
| EBITDA | 1,764 | 7,937 | -6,162 | -14,062 | -5,860 | Upgrade
|
| EBITDA Margin | 2.01% | 11.13% | -11.95% | -24.43% | -13.44% | Upgrade
|
| D&A For EBITDA | 3,564 | 3,228 | 3,643 | 5,552 | 2,179 | Upgrade
|
| EBIT | -1,800 | 4,709 | -9,806 | -19,615 | -8,039 | Upgrade
|
| EBIT Margin | -2.05% | 6.60% | -19.02% | -34.08% | -18.44% | Upgrade
|
| Advertising Expenses | 343.73 | 617.32 | 1,688 | 4,419 | 1,037 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.